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Abstract: Biglycan (BGN), an extracellular matrix component, has been reported to play a crucial role in the tumor 
progression of various cancers. However, the relation between the expression of BGN and clinical prognosis has 
not been studied yet. We therefore carry out the present study to elucidate the role of BGN in predicting outcomes 
of patients with esophageal squamous cell carcinoma (ESCC). In this study, the expression of BGN in 170 cases 
of ESCC tissues and matched 46 adjacent non-tumorous tissues was measured by quantitative real-time PCR and 
immunohistochemistry. Upregulation of BGN occurred in approximately 60% of primary ESCCs compared with their 
non-tumor counterparts. In addition, high expression of BGN was significantly associated with clinical stage (P 
= 0.009), tumor invasion (P = 0.006) and lymph node metastasis (P = 0.046). The 5-year disease-specific sur-
vival (DSS) in high expression of BGN group is poorer than that in low level expression group (36.8% VS 57.4%, 
P = 0.006). Stratified analysis according to the pathological stage revealed its discernibility on DSS was only pro-
nounced in patients with advanced clinical stage (P = 0.010). Cox multivariate analysis revealed that pathologic N 
category (P < 0.001; hazard ratio, 2.482, 95% CI, 1.576-3.909) and BGN expression (P = 0.019; hazard ratio, 1.713, 
95% CI, 1.092-2.688) were two independent prognostic factors. The findings of the present study provide evidence 
that BGN represents a potential novel prognostic biomarker for resected ESCC patients in advanced clinical stage.
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Introduction
Esophageal cancer (EC) has been ranked as 
the eighth most common malignancy and the 
sixth leading cause of cancer-related mortality 
worldwide, with incidence that varies greatly by 
geographic locations and ethnicity [1, 2]. His- 
tologically, esophageal squamous cell carcino-
ma (ESCC), the most prevalent pathological 
type of EC, predominates in east countries, par-
ticularly in China, with a proportion of more 
than 90% of all EC [3, 4]. Despite tremendous 
progress in diagnosis and therapeutic options, 
the average overall 5-year survival rate for 
ESCC is approximately 10-41% [5-7]. To date, 
extensive molecular biology studies of ESCC 
have identified a mass of dysregulated molecu-
lar events involved in esophageal carcinogene-
sis, which cover a wide range of genes with 
diverse functions. However, the reliable bio-
markers for high-risk population screening, for 
clinical diagnosis and prognosis, for evaluation 
of treatment efficiency are still lacking. There- 
fore, it is imperative to identify and characterize 
more effective biomarkers for such purposes.
With the advent of next-generation sequencing 
technologies in recent years, transcriptome 
sequencing (RNA-Seq), a new sequencing plat-
form, has been applied to delineate changes at 
the transcriptomic level in the study of cancer. 
Recently, our group performed a RNA-Seq to 
investigate differential gene expression in 
twelve non-tumor and ESCC clinical samples. 
About 1,598 up-regulated genes were identi-
fied including biglycan (BGN). Extracellular 
matrix (ECM) is the non-cellular component of 
tissues, which not only provides mechanical 
structural support but also takes part in the 
regulating the behavior of the cells. Every tissue 
BGN in ESCC
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has an ECM with unique composition and topol-
ogy that governs the process of determination, 
differentiation, proliferation, migration and 
regeneration of cells [8]. BGN is a member of 
the small leucine-rich proteoglycan (SLRP) fam-
ily of proteoglycans found in ECM, which is 
characterized by a core protein with centrally 
located leucine-rich repeat motifs flanked by 
disulfide bond stabilized loops [9]. BGN is dis-
tinctly expressed at the cell surface or in the 
pericellular matrix in various tissues of mainly 
mesenchymal origin [10], and is functionally 
involved in matrix assembly, cellular migration 
and adhesion, and the regulation of growth 
follow-up data. Ethical approval for this study 
was granted by the Medical Ethics Committee 
of Sun Yat-Sen University Cancer Center. All 
patients signed informed consent.
Quantitative real-time polymerase chain reac-
tion (qPCR)
The fresh tumorous and non-tumorous samples 
were taken from regions which macroscopically 
judged to be neoplastic and normal, respective-
ly. Both of them were immediately stored at dry 
ice after resection and then frozen at -80°C. 
Total RNA was extracted from clinical samples 
Table 1. Primer sequences used for qPCR analyses
Gene Sequence Accession No.
BGN q-F 5’- CTGGCATCCCCAAAGACCTC -3’ NM_001711.4
BGN q-R 5’- GCTCCCGTTCTCGATCATCC -3’
GAPDH q-F 5’- ACTTCAACAGCGACACCCACTC -3’ NM_001256799.1
GAPDH q-R 5’- TACCAGGAAATGAGCTTGACAAAG -3’
factor [11, 12]. BGN expression 
is associated with morphologi-
cal changes of cellular hypertro-
phy and well-formed actin stress 
fibers, characteristic of epitheli-
al-to-mesenchymal transdiffer-
entiation [13, 14]. Recently, 
overexpression of BGN has 
been detected in a variety of 
human epithelial tumors, includ-
ing colon [15, 16], ovary [17], 
liver [18], pancreas [19] and 
odontogenic [20], suggesting an 
important role of BGN in the 
pathogenesis, progression and 
therapy of cancer. Nonetheless, 
the relationship between BGN 
expression and clinical progno-
sis in ESCC need to be further 
elucidated. Thus, the purpose of 
present study is to verify the 
BGN expression in primary ESCC 
and analyze the correlation with 
clinical parameters.
Materials and methods
Patients and tissue samples
170 primary ESCC tumor tissues 
and 46 paired adjacent non-
tumorous tissues were collected 
immediately after surgery resec-
tion at Sun Yat-Sen University 
Cancer Center from March 2002 
to October 2008. The inclusion 
criteria were as follows: (a) histo-
logical proof of thoracic ESCC; 
(b) complete surgical resection 
(R0); (c) no neoadjuvant or adju-
vant treatment; (d) complete 





low level (%) high level (%)
Age (years old) 0.913
    ≤ 59 90 42 (46.7%) 48 (53.3%)
    > 59 80 38 (47.5%) 42 (52.5%)
Gender 0.762
    Male 123 57 (46.3%) 66 (53.7%)
    Female 47 23 (48.9%) 24 (51.1%)
Location 0.660
    Upper 34 18 (52.9%) 16 (47.1%)
    Middle 95 42 (44.2%) 53 (55.8%)
    Lower 41 20 (48.8%) 21 (51.2%)
Differentiation 0.988
    Grade 1 37 17 (45.9%) 20 (54.1%)
    Grade 2 93 44 (47.3%) 49 (52.7%)
    Grade 3 40 19 (47.5%) 21 (52.5%)
pT category 0.006
    T1-2 39 26 (66.7%) 13 (33.3%)
    T3-4 131 54 (41.2%) 77 (58.8%)
pN category 0.046
    N0 90 49 (54.4%) 41 (45.6%)
    N1 80 31 (38.8%) 49 (61.2%)
Clinical stage 0.009
    Early (I-II) 94 53 (56.3%) 41 (43.6%)
    Advanced (III) 76 27 (35.5%) 49 (64.5%)
Statistical significance (P < 0.05) is shown in bold.
BGN in ESCC
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using TRIzol reagent (Invitrogen), and was 
reverse-transcribed with random primers using 
an Advantage RT-for-PCR Kit (Clontech Lab- 
oratories) according to the manufacturer’s 
instructions. qPCR was performed to detect 
levels of the corresponding GAPDH and BGN 
using a SYBR Green PCR Kit (Applied Bio- 
systems) and an ABI 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Foster City, 
CA). The GAPDH was used as an internal con-
trol for BGN. The primers of BGN and GAPDH 
were listed in Table 1. The relative levels of 
expression were quantified and analyzed by 
using SDS 2.3 software (Applied Biosystems). 
The real-time value for each sample was aver-
aged and compared using the Ct method. 
ΔΔCt(sample) = ΔCt(sample) - ΔCt(calibrator), 
ΔCt(sample) = Ct(sample) of BGN - Ct(sample) 
of GAPDH; ΔCt(calibrator) = Ct(calibrator) of 
BGN - Ct(calibrator) of GAPDH; calibrator was 
Figure 1. A and B: BGN was up-regulated in ESCC. 
BGN mRNA was markedly increased in tumor tis-
sues than that in paired adjacent non-tumorous 
tissues. **, P < 0.0001, paired t-test.
Figure 2. Representative of BGN expression in adjacent non-tumorous tissue and ESCC tumor tissues detected by 
immunostaining with anti-BGN antibody (brown). The slide was counterstained with hematoxylin (original magnifica-
tion × 200).
BGN in ESCC
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defined as the pooled samples from 46 adja-
cent non-tumorous tissues.
ESCC tissue microarray (TMA) and immunohis-
tochemical (IHC) staining
A total of 170 formalin-fixed, paraffin-embed-
ded ESCC tumor specimens and 46 corre-
sponding adjacent non-tumorous tissues were 
selected from Sun Yat-Sen University Cancer 
Center. The ESCC TMA was constructed as 
described previously [21]. Briefly, tissue sec-
tions with 5 μm thick were cut from the tissue 
microarray blocks and mounted on microscope 
slides. The IHC staining was performed using 
TMA slides that were deparaffinized in xylene, 
rehydrated through a graded alcohol series and 
incubated with 3% hydrogen peroxide. For anti-
gen retrieval, TMA slides were boiled by a pres-
sure cooker in 10 mM sodium citrate buffer (pH 
6.0) for 15 minutes. The slides were blocked by 
10% normal goat serum at room temperature 
for 30 minutes and then incubated with rabbit 
polyclonal antibody against BGN (Abgent) at a 
dilution of 1:200 at 4°C overnight. Immu- 
noreactivity was visualized using an Envision 
detection system (DAKO), and the nuclei were 
counterstained with hematoxylin. An immuno-
reactivity score (IRS) system was applied as 
described previously [22]. The percentage of 
BGN-positive cells was scored as 0, < 5%, neg-
ative; 1, 5%-25%, sporadic; 2, 25%-50%, focal; 
3, > 50%, diffuse. The intensity of BGN-positive 
staining was scored as 0, negative; 1, weak; 2, 
moderate; 3, strong. Both the percent of posi-
tive cells and cell staining intensity were decid-
ed in a double-blinded manner. The total score 
was determined by the following formula: 
Staining index = intensity × positive rate. In the 
present study, staining index ≤ 4 was consid-
ered low expression, and staining index > 4 was 
considered as high expression.
Statistical analysis
Statistical analysis was performed using the 
Statistical Package for the Social Sciences 
(SPSS) version 16.0 (SPSS Inc, Chicago, IL). 
Paired two-tailed t-test was employed to com-
pare the expression of BGN in primary ESCC 
tumors and their corresponding adjacent non-
tumorous tissues. The correlation between 
BGN expression and clinicopathologic charac-
teristics was assessed by χ2 or Fisher’s exact 
tests. Disease-specific survival was calculated 
from the time of surgery to either the time of 
death from ESCC or last follow up (31 December 
2011). The prognostic value was calculated by 
the Kaplan-Meier analysis with log-rank test. 
Univariate and multivariate survival analysis 
was performed using the Cox proportional haz-
ard model with a forward stepwise procedure 
(the entry and removal probabilities were 0.05 
and 0.10, respectively). A significant difference 
was considered statistically when P value was 
< 0.05.
Figure 3. A: The correlation of expression of BGN and prognosis of patients with ESCC. Kaplan-Meier curves with 
univariate analysis showed that patients with high expression of BGN had a poorer disease specific survival than 
those with low expression of BGN. P = 0.006, log-rank test. B: Stratified survival analysis according to the pathologi-
cal stage revealed discernibility of BGN expression on DSS was only pronounced in patients with advanced clinical 
stage (pStage III). P = 0.010, log-rank test.
BGN in ESCC
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Results
Characteristics of ESCC patients
According to the inclusion criteria, 170 patients 
with ESCC were recruited in this study. There 
were 123 male and 47 female patients, with a 
mean age of 58.1 years (range 30-88 years). 
Other clinical and pathological parameters 
were shown in Table 2. The follow-up data were 
obtained from all the patients, with a median 
survival of 54 months (range 2-105 months). 
with their non-tumor counterparts (P < 0.001, 
t-test; Figure 1B). BGN expression in protein 
level was further studied in 46 primary ESCCs 
by IHC using a tissue microarray. BGN localized 
at the cytoplasm of esophageal epithelial cells 
and ESCC cells. Upregulation of BGN was 
detected in 26/46 (56.5%) of ESCC tissues 
compared with their adjacent non-tumor tis-
sues (P < 0.001, t-test; Figure 2).
Clinicopathologic features of BGN in ESCC 
patients
We next examined the correlation between the 
expression of BGN and the clinicopathological 
characteristics of ESCC. High-level expression 
of BGN was detected in 90/170 (52.9%) of 
informative ESCC tissues. The correlation 
between BGN expression status and clinico-
pathologic features of ESCC was further evalu-
ated, which was summarized in Table 2. The 
results showed that BGN expression was sig-
Table 3. Univariate analysis of BGN expression and clinicopathologi-
cal factors for disease-specific survival in ESCC
Clinical features Cases
Disease-specific Survival (DSS) (%)
P valuea
1-year DSS 3-year DSS 5-year DSS
Age (years old) 0.214
    ≤ 59 90 83.0 58.0 53.9
    > 59 80 88.8 54.0 37.5
Gender 0.903
    Male 123 84.4 55.4 48.2
    Female 47 89.4 58.1 43.5
Location 0.655
    Upper 34 88.2 60.3 53.7
    Middle 95 88.3 56.5 44.0
    Lower 41 77.7 51.9 38.9
Differentiation 0.202
    Grade 1 37 81.1 63.5 54.1
    Grade 2 93 86.9 59.9 51.7
    Grade 3 40 87.5 40.8 31.1
pT category 0.272
    T1-2 39 89.5 57.9 57.9
    T3-4 131 84.7 55.5 43.2
pN category < 0.001
    N0 90 91.0 70.8 59.7
    N1 80 80.0 39.7 32.4
BGN expression 0.006
    Low 80 89.8 66.1 57.4
    High 90 82.2 47.4 36.8
aKaplan-Meier method, log-rank test.
Table 4. Multivariate survival analysisa for dis-
ease-specific survival in patients with ESCC
Clinical features p value HRb 95% CIc
pN category < 0.001 2.482 1.576-3.909
BGN expression  0.019 1.713 1.092-2.688
aCox’s proportional hazards regression analysis (Forward 
stepwise); bHR, hazard ratio; c95% CI, 95% confidence 
interval.
Patients who died from dis-
eases other than ESCC or 
from unexpected events 
were excluded from the stu- 
dy. According to the 7th edi-
tion AJCC staging system 
[23] and our demographic 
data, the clinicopathologic 
features were dichotomized 
for statistical analyses as 
shown in Table 2.
The expression of BGN in 
ESCC and non-tumorous 
tissues
The mRNA expression of 
BGN was initially tested in 
46 pairs of primary ESCC 
tumors and their corre-
sponding adjacent non-
tumorous tissues by qPCR. 
Up-regulation of BGN was 
detected in 28/46 (60.9%) 
of ESCC tumors compared 
with their normal counter-
parts (defined as a 2-fold 
higher of BGN expression 
in non-tumor counterparts) 
(Figure 1A). The relative ex- 
pression level of BGN was 
significantly up-regulated in 
tumor tissues compared 
BGN in ESCC
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nificantly associated with pathologic T category 
(P = 0.006), pathologic N category (P = 0.046) 
and clinical stage (P = 0.009). No correlation 
was observed between BGN expression and 
patient’s age (P = 0.913), gender (P = 0.762), 
tumor location (P = 0.660) and tumor cell histo-
logical differentiation (P = 0.988; Table 2).
Association between BGN expression and 
patient survival
Kaplan-Meier analysis showed that a high-level 
expression of BGN was significantly associated 
with poorer disease-specific survival (DSS) of 
resected ESCC patients (P = 0.006). The 5-year 
DSSs of ESCC patients in high and low level 
expression groups were 36.8% and 57.4%, 
respectively (Figure 3A and Table 3). In a strati-
fied survival analysis according to the patho-
logical stage, no significant difference in DSS 
was observed in patients with early clinical 
stage (pStage I and II) (P = 0.704). However, 
BGN expression could differentiate the progno-
sis of patients in advanced clinical stage 
(pStage III) (P = 0.010, Figure 3B). Further, by 
multivariate survival analysis including patho-
logic N category and BGN expression which had 
impact on survival of patients, we found that 
pathologic N category (P < 0.001) and BGN 
expression (P = 0.019) were two independent 
prognostic predictors for resected ESCC 
patients enrolled in this study (Table 4).
Discussion
There is ample evidence that the small leucine-
rich proteoglycans (SLRPs) are among the key 
players in the tumor microenvironment and 
involved in the matrix assembly, cellular migra-
tion and adhesion, cell growth, and apoptosis 
[12, 24]. BGN, as one of the best studied mem-
ber of the SLPRs, has been reported that its up-
regulated expression is associated with cancer 
progression [15, 17, 18, 20, 25]. Here in this 
study, we found that approximately 60% of 
ESCC patients showed elevated BGN expres-
sion in their tumorous specimens. BGN has 
been reported to positively regulate cell prolif-
eration, through cdk2- and p27-dependent 
pathways [26]. It is also proved to enhance the 
activation of the Wnt/β-catenin pathway 
through a direct interaction of its core protein 
with Wnt ligand and its coreceptor, LRP6 [27]. 
These results lead the hypothesis that BGN 
may induce the proliferation and/or inhibit the 
apoptosis of ESCC cells. However, other several 
studies suggest that BGN may serve as a nega-
tive growth regulator: anti-proliferative effects 
on pancreatic tumor cells in vitro by inducing 
G1 phase cell cycle arrest [19]; anti-apoptotic 
effects on mesangial cells via inhibiting the 
activity of caspase-3 [28]. Based on these 
studies, BGN seems to display very contradict-
ing roles dependent on cellular context. 
Thereby, further studies in vitro and in vivo are 
needed to elucidate the precise mechanisms of 
BGN that involved in the progression of ESCC.
Furthermore, in this study, the genetic-clinico-
pathologic correlation analysis found that a 
high expression level of BGN was observed 
more frequently in patients with tumor invasion 
(P = 0.006), lymph node metastasis (P = 0.046) 
and advanced clinical stage (P = 0.009). A 
recent study which indicated that up-regulated 
BGN was associated with tumor metastasis via 
a microarray profiling of 15 adjacent normal/
tumor-matched ESCC specimens confirmed our 
results [29]. These findings agree with the fact 
that proteoglycans, as prominent constituents 
of both the extracellular matrix and the cell sur-
face, are proposed to play roles in cell adhe-
sion, growth factor interactions, and matrix 
assembly [30, 31]. A hand-full of studies have 
now been conducted to investigate the molecu-
lar mechanism of BGN involved in metastasis. 
Tufvesson et al. has previously reported that 
BGN and decorin could induce morphological 
and cytoskeletal changes involving signaling by 
the small GTPases RhoA and Rac1, resulting in 
lung fibroblast migration [13]. In addition, BGN 
was found to inhibit cell adhesion on type I col-
lagen and fibronectin via its binding to these 
substrates [28]. In the BGN transgenic mice, 
BGN may directly or indirectly activate TGF-β 
[32]. Of interest, it has been reported that BGN 
is specifically expressed in tumor endothelial 
cells, and serum BGN levels are higher in can-
cer patients than in healthy volunteers [33]. In 
light of the present investigation we postulate 
that BGN secreted from tumor endothelial cells 
into blood flow might be of diagnostic value in 
ESCC patients with advanced clinical stage. 
Nonetheless, further investigation with a larger 
sample size is needed to confirm these find-
ings. On the other hand, Yamamoto et al. also 
found that BGN could act as an angiogenic fac-
tor stimulating TEC migration and tube forma-
tion in an autocrine manner through TLR2 and 
BGN in ESCC
2503 Int J Clin Exp Pathol 2013;6(11):2497-2505
TLR4 [33]. Thus, this may indicate BGN could 
be a novel target for anti-tumor, as well as anti-
angiogenic therapy without injuring normal 
blood vessels to ESCC patients with advanced 
clinical stage in future.
Our study also demonstrated that high expres-
sion of BGN was one of the most important 
prognosis factors of poor disease-specific sur-
vival in the univariate and multivariate analysis. 
The 5-year disease-specific survival of patients 
with high BGN expression was markedly short-
er than that with low expression (36.8 vs. 
57.4%). Moreover, we analyzed the prognostic 
value of BGN expression level in selected 
patient subgroups, and found that in subgroup 
of patients with advanced clinical stage, higher 
BGN expression was associated with a poorer 
DSS. Adjuvant chemotherapy [34, 35] or neo-
adjuvant chemoradiotherapy [36-40] was prov-
en to improve the clinical outcome of patients 
with locally advanced ESCC, compared with 
surgery alone. Therefore, postoperative adju-
vant chemotherapy may be recommended for 
the subset of patients with high expression of 
BGN to improve their outcome.
In conclusion, the results of present study, for 
the first time, demonstrated that high expres-
sion of BGN in ESCC tumorous specimens indi-
cated aggressive tumor behaviors and predict-
ed a worse clinical outcome. These finding 
suggested that BGN may serve as a potential 
target for diagnostic and anti-angiogenic thera-
py to ESCC patients, especially the patients 
with advanced clinical stage.
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